Canadian Milka Chocolate Bars Recalled Due to Undeclared Nuts
A recall has been initiated in seven Canadian provinces for a chocolate bar sold by the Swiss company Milka due to undeclared hazelnuts.
Milka brand Bubbly Alpine Milk “Chocolat” is being removed from store shelves because it contains hazelnuts, an ingredient not listed on the packaging, as stated by the Canadian Food Inspection Agency (CFIA) in a Jan. 14 advisory.
The chocolate bars are available in British Columbia, Alberta, Ontario, Quebec, New Brunswick, Nova Scotia, and Newfoundland and Labrador, according to the food inspection agency. They are also sold on Amazon.
The recalled chocolate bar weighs 90 grams and has a Universal Product Code (UPC) of 7 622210 371638, as reported by the CFIA.
After a consumer complaint, the recall was initiated, with one reported reaction linked to the consumption of the product, noted the agency.
CFIA recommends individuals with hazelnut allergies or sensitivities to avoid consuming the product, as hazelnuts are a member of the tree nut family.
Related Stories
The agency is ensuring that industry removes the recalled products from the market and conducting a food safety investigation that may lead to the recall of other products.
Mondelēz International, the owner of Milka chocolate brand, has not yet issued a statement regarding the recall. The Epoch Times reached out to the company for comment but did not receive a response before publication.
Mondelēz International has owned the Milka brand since 2012. The company also owns popular brands like Ritz, Oreo, and Clif Bar. Milka Chocolate products are sold in over 15 countries.
Hazelnut Allergy Symptoms
Health Canada mentions that hazelnut and other tree nut allergies can cause reactions from mild, like hives, to severe, like anaphylaxis.
Additional allergic reactions include swelling of the face, lips, tongue, itching, warmth, redness, coughing, wheezing, and gastrointestinal issues, as stated on the Health Canada website.
Severe reactions may present with pale or blue-tinged skin, weak pulse, dizziness, trouble swallowing, or loss of consciousness.
In instances of anaphylaxis, individuals may experience difficulty breathing, drop in blood pressure, shock, loss of consciousness, and potentially death.
The sole treatment for anaphylaxis is an injection of epinephrine using an auto-injector device such as an EpiPen, as stated by the health agency.
